Interaction Checker

Glycerol phenylbutyrate interactions

Glycerol phenylbutyrate (Ravicti) has 64 documented interactions across the FDA labels and fact sheets we index: 0 major, 30 moderate, 34 minor, and 0 where a label reports no significant interaction. Each entry below quotes the sentence behind it. This drug page is a starting point, not a verdict for your situation.

Interactions from the label

Moderate interactions (30)

  • Azelastine and fluticasoneantihistamineModerate

    Corticosteroids, valproic acid, or haloperidol : May increase plasma ammonia level; monitor ammonia levels closely. (Glycerol phenylbutyrate label, Drug interactions)

  • BeclomethasonecorticosteroidModerate

    Corticosteroids, valproic acid, or haloperidol : May increase plasma ammonia level; monitor ammonia levels closely. (Glycerol phenylbutyrate label, Drug interactions)

  • BetamethasonecorticosteroidModerate

    Corticosteroids, valproic acid, or haloperidol : May increase plasma ammonia level; monitor ammonia levels closely. (Glycerol phenylbutyrate label, Drug interactions)

  • BudesonidecorticosteroidModerate

    Corticosteroids, valproic acid, or haloperidol : May increase plasma ammonia level; monitor ammonia levels closely. (Glycerol phenylbutyrate label, Drug interactions)

  • Budesonide and formoterolcorticosteroidModerate

    Corticosteroids, valproic acid, or haloperidol : May increase plasma ammonia level; monitor ammonia levels closely. (Glycerol phenylbutyrate label, Drug interactions)

  • CiclesonidecorticosteroidModerate

    Corticosteroids, valproic acid, or haloperidol : May increase plasma ammonia level; monitor ammonia levels closely. (Glycerol phenylbutyrate label, Drug interactions)

  • ClobetasolcorticosteroidModerate

    Corticosteroids, valproic acid, or haloperidol : May increase plasma ammonia level; monitor ammonia levels closely. (Glycerol phenylbutyrate label, Drug interactions)

  • CyclosporineimmunosuppressantModerate

    CYP3A4 Substrates with narrow therapeutic index (e.g., alfentanil, quinidine, cyclosporine) : Glycerol phenylbutyrate may decrease exposure; monitor for decreased efficacy of the narrow therapeutic index drug ( 7.3 ) (Glycerol phenylbutyrate label, Drug interactions)

  • DeflazacortcorticosteroidModerate

    Corticosteroids, valproic acid, or haloperidol : May increase plasma ammonia level; monitor ammonia levels closely. (Glycerol phenylbutyrate label, Drug interactions)

  • DesonidecorticosteroidModerate

    Corticosteroids, valproic acid, or haloperidol : May increase plasma ammonia level; monitor ammonia levels closely. (Glycerol phenylbutyrate label, Drug interactions)

  • DexamethasonecorticosteroidModerate

    Corticosteroids, valproic acid, or haloperidol : May increase plasma ammonia level; monitor ammonia levels closely. (Glycerol phenylbutyrate label, Drug interactions)

  • Dextromethorphan and quinidineserotonergic drugModerate

    CYP3A4 Substrates with narrow therapeutic index (e.g., alfentanil, quinidine, cyclosporine) : Glycerol phenylbutyrate may decrease exposure; monitor for decreased efficacy of the narrow therapeutic index drug ( 7.3 ) (Glycerol phenylbutyrate label, Drug interactions)

  • FludrocortisonecorticosteroidModerate

    Corticosteroids, valproic acid, or haloperidol : May increase plasma ammonia level; monitor ammonia levels closely. (Glycerol phenylbutyrate label, Drug interactions)

  • FlunisolidecorticosteroidModerate

    Corticosteroids, valproic acid, or haloperidol : May increase plasma ammonia level; monitor ammonia levels closely. (Glycerol phenylbutyrate label, Drug interactions)

  • FluocinonidecorticosteroidModerate

    Corticosteroids, valproic acid, or haloperidol : May increase plasma ammonia level; monitor ammonia levels closely. (Glycerol phenylbutyrate label, Drug interactions)

  • FluticasonecorticosteroidModerate

    Corticosteroids, valproic acid, or haloperidol : May increase plasma ammonia level; monitor ammonia levels closely. (Glycerol phenylbutyrate label, Drug interactions)

  • Fluticasone and salmeterolcorticosteroidModerate

    Corticosteroids, valproic acid, or haloperidol : May increase plasma ammonia level; monitor ammonia levels closely. (Glycerol phenylbutyrate label, Drug interactions)

  • HalobetasolcorticosteroidModerate

    Corticosteroids, valproic acid, or haloperidol : May increase plasma ammonia level; monitor ammonia levels closely. (Glycerol phenylbutyrate label, Drug interactions)

  • HaloperidolantipsychoticModerate

    Corticosteroids, valproic acid, or haloperidol : May increase plasma ammonia level; monitor ammonia levels closely. (Glycerol phenylbutyrate label, Drug interactions)

  • HydrocortisonecorticosteroidModerate

    Corticosteroids, valproic acid, or haloperidol : May increase plasma ammonia level; monitor ammonia levels closely. (Glycerol phenylbutyrate label, Drug interactions)

  • MethylprednisolonecorticosteroidModerate

    Corticosteroids, valproic acid, or haloperidol : May increase plasma ammonia level; monitor ammonia levels closely. (Glycerol phenylbutyrate label, Drug interactions)

  • MidazolambenzodiazepineModerate

    Midazolam : Decreased exposure; monitor for suboptimal effect of midazolam.( 7.3 ) (Glycerol phenylbutyrate label, Drug interactions)

  • MometasonecorticosteroidModerate

    Corticosteroids, valproic acid, or haloperidol : May increase plasma ammonia level; monitor ammonia levels closely. (Glycerol phenylbutyrate label, Drug interactions)

  • Olopatadine and mometasoneantihistamineModerate

    Corticosteroids, valproic acid, or haloperidol : May increase plasma ammonia level; monitor ammonia levels closely. (Glycerol phenylbutyrate label, Drug interactions)

  • PrednisolonecorticosteroidModerate

    Corticosteroids, valproic acid, or haloperidol : May increase plasma ammonia level; monitor ammonia levels closely. (Glycerol phenylbutyrate label, Drug interactions)

  • PrednisonecorticosteroidModerate

    Corticosteroids, valproic acid, or haloperidol : May increase plasma ammonia level; monitor ammonia levels closely. (Glycerol phenylbutyrate label, Drug interactions)

  • QuinidineantiarrhythmicModerate

    CYP3A4 Substrates with narrow therapeutic index (e.g., alfentanil, quinidine, cyclosporine) : Glycerol phenylbutyrate may decrease exposure; monitor for decreased efficacy of the narrow therapeutic index drug ( 7.3 ) (Glycerol phenylbutyrate label, Drug interactions)

  • Sodium phenylacetate and sodium benzoateModerate

    In a study of adult cancer patients, subjects received sodium phenylacetate administered as a 1-hour infusion twice daily at two dose levels of 125 and 150 mg/kg for a 2-week period. (Glycerol phenylbutyrate label, Warnings and precautions)

  • TriamcinolonecorticosteroidModerate

    Corticosteroids, valproic acid, or haloperidol : May increase plasma ammonia level; monitor ammonia levels closely. (Glycerol phenylbutyrate label, Drug interactions)

  • Valproic acidanticonvulsantModerate

    Corticosteroids, valproic acid, or haloperidol : May increase plasma ammonia level; monitor ammonia levels closely. (Glycerol phenylbutyrate label, Drug interactions)

Minor mentions (34)

  • AprepitantCYP3A4 inhibitorMinor

    Potential for Glycerol Phenylbutyrate to Affect Other Drugs Drugs with narrow therapeutic index that are substrates of CYP3A4 Glycerol phenylbutyrate is a weak inducer of CYP3A4 in humans. (Glycerol phenylbutyrate label, Drug interactions)

  • ArmodafinilCNS stimulantMinor

    Potential for Glycerol Phenylbutyrate to Affect Other Drugs Drugs with narrow therapeutic index that are substrates of CYP3A4 Glycerol phenylbutyrate is a weak inducer of CYP3A4 in humans. (Glycerol phenylbutyrate label, Drug interactions)

  • BosentanCYP3A4 inducerMinor

    Potential for Glycerol Phenylbutyrate to Affect Other Drugs Drugs with narrow therapeutic index that are substrates of CYP3A4 Glycerol phenylbutyrate is a weak inducer of CYP3A4 in humans. (Glycerol phenylbutyrate label, Drug interactions)

  • CarbamazepineanticonvulsantMinor

    Potential for Glycerol Phenylbutyrate to Affect Other Drugs Drugs with narrow therapeutic index that are substrates of CYP3A4 Glycerol phenylbutyrate is a weak inducer of CYP3A4 in humans. (Glycerol phenylbutyrate label, Drug interactions)

  • CenobamateanticonvulsantMinor

    Potential for Glycerol Phenylbutyrate to Affect Other Drugs Drugs with narrow therapeutic index that are substrates of CYP3A4 Glycerol phenylbutyrate is a weak inducer of CYP3A4 in humans. (Glycerol phenylbutyrate label, Drug interactions)

  • ClobazambenzodiazepineMinor

    Potential for Glycerol Phenylbutyrate to Affect Other Drugs Drugs with narrow therapeutic index that are substrates of CYP3A4 Glycerol phenylbutyrate is a weak inducer of CYP3A4 in humans. (Glycerol phenylbutyrate label, Drug interactions)

  • Deferasiroxiron supplementMinor

    Potential for Glycerol Phenylbutyrate to Affect Other Drugs Drugs with narrow therapeutic index that are substrates of CYP3A4 Glycerol phenylbutyrate is a weak inducer of CYP3A4 in humans. (Glycerol phenylbutyrate label, Drug interactions)

  • EfavirenzantiretroviralMinor

    Potential for Glycerol Phenylbutyrate to Affect Other Drugs Drugs with narrow therapeutic index that are substrates of CYP3A4 Glycerol phenylbutyrate is a weak inducer of CYP3A4 in humans. (Glycerol phenylbutyrate label, Drug interactions)

  • Efavirenz, lamivudine, and tenofovirantiretroviralMinor

    Potential for Glycerol Phenylbutyrate to Affect Other Drugs Drugs with narrow therapeutic index that are substrates of CYP3A4 Glycerol phenylbutyrate is a weak inducer of CYP3A4 in humans. (Glycerol phenylbutyrate label, Drug interactions)

  • EslicarbazepineanticonvulsantMinor

    Potential for Glycerol Phenylbutyrate to Affect Other Drugs Drugs with narrow therapeutic index that are substrates of CYP3A4 Glycerol phenylbutyrate is a weak inducer of CYP3A4 in humans. (Glycerol phenylbutyrate label, Drug interactions)

  • EtravirineantiretroviralMinor

    Potential for Glycerol Phenylbutyrate to Affect Other Drugs Drugs with narrow therapeutic index that are substrates of CYP3A4 Glycerol phenylbutyrate is a weak inducer of CYP3A4 in humans. (Glycerol phenylbutyrate label, Drug interactions)

  • FosphenytoinanticonvulsantMinor

    Potential for Glycerol Phenylbutyrate to Affect Other Drugs Drugs with narrow therapeutic index that are substrates of CYP3A4 Glycerol phenylbutyrate is a weak inducer of CYP3A4 in humans. (Glycerol phenylbutyrate label, Drug interactions)

  • GriseofulvinantifungalMinor

    Potential for Glycerol Phenylbutyrate to Affect Other Drugs Drugs with narrow therapeutic index that are substrates of CYP3A4 Glycerol phenylbutyrate is a weak inducer of CYP3A4 in humans. (Glycerol phenylbutyrate label, Drug interactions)

  • Lopinavir and ritonavirantiretroviralMinor

    Potential for Glycerol Phenylbutyrate to Affect Other Drugs Drugs with narrow therapeutic index that are substrates of CYP3A4 Glycerol phenylbutyrate is a weak inducer of CYP3A4 in humans. (Glycerol phenylbutyrate label, Drug interactions)

  • LorlatinibCYP3A4 inducerMinor

    Potential for Glycerol Phenylbutyrate to Affect Other Drugs Drugs with narrow therapeutic index that are substrates of CYP3A4 Glycerol phenylbutyrate is a weak inducer of CYP3A4 in humans. (Glycerol phenylbutyrate label, Drug interactions)

  • MitapivatCYP3A4 inducerMinor

    Potential for Glycerol Phenylbutyrate to Affect Other Drugs Drugs with narrow therapeutic index that are substrates of CYP3A4 Glycerol phenylbutyrate is a weak inducer of CYP3A4 in humans. (Glycerol phenylbutyrate label, Drug interactions)

  • MitotaneCYP3A4 inducerMinor

    Potential for Glycerol Phenylbutyrate to Affect Other Drugs Drugs with narrow therapeutic index that are substrates of CYP3A4 Glycerol phenylbutyrate is a weak inducer of CYP3A4 in humans. (Glycerol phenylbutyrate label, Drug interactions)

  • ModafinilCNS stimulantMinor

    Potential for Glycerol Phenylbutyrate to Affect Other Drugs Drugs with narrow therapeutic index that are substrates of CYP3A4 Glycerol phenylbutyrate is a weak inducer of CYP3A4 in humans. (Glycerol phenylbutyrate label, Drug interactions)

  • Nafcillinpenicillin antibioticMinor

    Potential for Glycerol Phenylbutyrate to Affect Other Drugs Drugs with narrow therapeutic index that are substrates of CYP3A4 Glycerol phenylbutyrate is a weak inducer of CYP3A4 in humans. (Glycerol phenylbutyrate label, Drug interactions)

  • NevirapineantiretroviralMinor

    Potential for Glycerol Phenylbutyrate to Affect Other Drugs Drugs with narrow therapeutic index that are substrates of CYP3A4 Glycerol phenylbutyrate is a weak inducer of CYP3A4 in humans. (Glycerol phenylbutyrate label, Drug interactions)

  • OxcarbazepineanticonvulsantMinor

    Potential for Glycerol Phenylbutyrate to Affect Other Drugs Drugs with narrow therapeutic index that are substrates of CYP3A4 Glycerol phenylbutyrate is a weak inducer of CYP3A4 in humans. (Glycerol phenylbutyrate label, Drug interactions)

  • PhenobarbitalbarbiturateMinor

    Potential for Glycerol Phenylbutyrate to Affect Other Drugs Drugs with narrow therapeutic index that are substrates of CYP3A4 Glycerol phenylbutyrate is a weak inducer of CYP3A4 in humans. (Glycerol phenylbutyrate label, Drug interactions)

  • Phentermine and topiramateCNS stimulantMinor

    Potential for Glycerol Phenylbutyrate to Affect Other Drugs Drugs with narrow therapeutic index that are substrates of CYP3A4 Glycerol phenylbutyrate is a weak inducer of CYP3A4 in humans. (Glycerol phenylbutyrate label, Drug interactions)

  • PhenytoinanticonvulsantMinor

    Potential for Glycerol Phenylbutyrate to Affect Other Drugs Drugs with narrow therapeutic index that are substrates of CYP3A4 Glycerol phenylbutyrate is a weak inducer of CYP3A4 in humans. (Glycerol phenylbutyrate label, Drug interactions)

  • PrimidoneanticonvulsantMinor

    Potential for Glycerol Phenylbutyrate to Affect Other Drugs Drugs with narrow therapeutic index that are substrates of CYP3A4 Glycerol phenylbutyrate is a weak inducer of CYP3A4 in humans. (Glycerol phenylbutyrate label, Drug interactions)

  • ProbenecidMinor

    Probenecid : May affect renal excretion of metabolites of glycerol phenylbutyrate, including phenylacetylglutamine (PAGN) and PAA. (Glycerol phenylbutyrate label, Drug interactions)

  • Probenecid and colchicineMinor

    Probenecid : May affect renal excretion of metabolites of glycerol phenylbutyrate, including phenylacetylglutamine (PAGN) and PAA. (Glycerol phenylbutyrate label, Drug interactions)

  • RifabutinantibioticMinor

    Potential for Glycerol Phenylbutyrate to Affect Other Drugs Drugs with narrow therapeutic index that are substrates of CYP3A4 Glycerol phenylbutyrate is a weak inducer of CYP3A4 in humans. (Glycerol phenylbutyrate label, Drug interactions)

  • RifampinantibioticMinor

    Potential for Glycerol Phenylbutyrate to Affect Other Drugs Drugs with narrow therapeutic index that are substrates of CYP3A4 Glycerol phenylbutyrate is a weak inducer of CYP3A4 in humans. (Glycerol phenylbutyrate label, Drug interactions)

  • RifapentineantibioticMinor

    Potential for Glycerol Phenylbutyrate to Affect Other Drugs Drugs with narrow therapeutic index that are substrates of CYP3A4 Glycerol phenylbutyrate is a weak inducer of CYP3A4 in humans. (Glycerol phenylbutyrate label, Drug interactions)

  • RitonavirantiretroviralMinor

    Potential for Glycerol Phenylbutyrate to Affect Other Drugs Drugs with narrow therapeutic index that are substrates of CYP3A4 Glycerol phenylbutyrate is a weak inducer of CYP3A4 in humans. (Glycerol phenylbutyrate label, Drug interactions)

  • Sodium phenylbutyrateMinor

    In clinical trials in patients with UCDs who had been on sodium phenylbutyrate prior to administration of glycerol phenylbutyrate, adverse reactions of headache, fatigue, symptoms of peripheral neuropathy, seizures, tremor and/or dizziness were reported. (Glycerol phenylbutyrate label, Warnings and precautions)

  • SuzetrigineCYP3A4 inducerMinor

    Potential for Glycerol Phenylbutyrate to Affect Other Drugs Drugs with narrow therapeutic index that are substrates of CYP3A4 Glycerol phenylbutyrate is a weak inducer of CYP3A4 in humans. (Glycerol phenylbutyrate label, Drug interactions)

  • TopiramateanticonvulsantMinor

    Potential for Glycerol Phenylbutyrate to Affect Other Drugs Drugs with narrow therapeutic index that are substrates of CYP3A4 Glycerol phenylbutyrate is a weak inducer of CYP3A4 in humans. (Glycerol phenylbutyrate label, Drug interactions)

Check Glycerol phenylbutyrate against everything you take. Add your full list; every pair is checked at once.

Open in the checker

Not medical advice. Severity reflects the label's wording, not your circumstances. A "major" flag can be routine under supervision and a "minor" one can matter at high doses. Ask a pharmacist.